Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert-Jan Hassing

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
British Journal of Clinical Pharmacology|January 9, 2026
Intravenous lanadelumab for the treatment of moderately ill COVID-19 patientsJob J Engel, Christine van Linge, W Joost Wiersinga, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2021
Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter TrialThijs Ten Doesschate, Sander Kuiper, Cees van Nieuwkoop, et al.
British Journal of Clinical Pharmacology|April 26, 2021
Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: A propensity score-matched cohort studyJanneke P Spiegelenberg, Marleen M H J van Gelder, Martje L Maas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2021
Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted PatientsArvind Gharbharan, Corine H GeurtsvanKessel, Carlijn C E Jordans, et al.
Open Forum Infectious Diseases|April 3, 2024
Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort StudyMarta Vasylyev, Ferdinand W N M Wit, Carlijn C E Jordans, et al.
Nature Communications|May 28, 2021
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infectionArvind Gharbharan, Carlijn C E Jordans, Corine GeurtsvanKessel, et al.
American Heart Journal|June 9, 2020
Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection DiseaseD H Frank Gommans, Joris Nas, Sara-Joan Pinto-Sietsma, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
British Journal of Clinical Pharmacology|January 9, 2026
Intravenous lanadelumab for the treatment of moderately ill COVID-19 patientsJob J Engel, Christine van Linge, W Joost Wiersinga, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2021
Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter TrialThijs Ten Doesschate, Sander Kuiper, Cees van Nieuwkoop, et al.
British Journal of Clinical Pharmacology|April 26, 2021
Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: A propensity score-matched cohort studyJanneke P Spiegelenberg, Marleen M H J van Gelder, Martje L Maas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2021
Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted PatientsArvind Gharbharan, Corine H GeurtsvanKessel, Carlijn C E Jordans, et al.
Open Forum Infectious Diseases|April 3, 2024
Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort StudyMarta Vasylyev, Ferdinand W N M Wit, Carlijn C E Jordans, et al.
Nature Communications|May 28, 2021
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infectionArvind Gharbharan, Carlijn C E Jordans, Corine GeurtsvanKessel, et al.
American Heart Journal|June 9, 2020
Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection DiseaseD H Frank Gommans, Joris Nas, Sara-Joan Pinto-Sietsma, et al.
Pageof 3